Is Travere Therapeutics, Inc. (NASDAQ:TVTX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Travere Therapeutics, Inc. at current levels.
FILSPARI is becoming the default IgAN therapy, and the market still treats Travere like a one-drug story with a question mark.
Where TVTX is headed
FILSPARI has done something rare in nephrology. It walked into a category dominated by ACE inhibitors and ARBs, picked up full FDA approval for IgA Nephropathy in 2024, and is now showing up in real prescribing patterns rather than just on KOL slide decks. Revenue grew 56% over the trailing twelve months, the gross margin sits near 56%, and management is guiding into a 207% earnings inflection next year. That is not a story about a hopeful launch. That is a drug finding its market.
Read the full Compass Direction on TVTX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $44.43).
See the full TVTX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Travere Therapeutics, Inc. (NASDAQ:TVTX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Travere Therapeutics, Inc. at current levels. FILSPARI is becoming the default IgAN therapy, and the market still treats Travere like a one-drug story with a question mark.
What is TVTX's Compass Score?
Travere Therapeutics, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TVTX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TVTX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.